Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aktis Oncology, Inc.AKTS · Entity 4711 | Director | January 12, 2026 | January 12, 2026 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director · PRESIDENT AND CEO | March 12, 2025 | March 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aktis Oncology, Inc.
Report date January 12, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 19,631 |
Reported balance
After 2026-01-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-01-12 · Conversion · Acquired 19,631 · Balance 19,631 F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration. F2: Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Conversion · Disposed 50,000 · Balance 0 F3: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-01-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-12 · Conversion · Disposed 24,687 · Balance 0 F3: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration.
F2: Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.
F3: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Repare Therapeutics Inc.
Report date March 12, 2025 · Filed March 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 124,394 |
Reported balance
After 2025-03-12 transaction · row 1
1 source rowRow 1 · 2025-03-12 · Sale · Disposed 21,179 · Balance 124,394 F1: Represent shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of restricted stock units and does not represent a discretionary sale by the holder. |
| Common SharesSEC Table I · non-derivative | IndirectSee footnote | 107,558 |
Reported balance
Holding disclosure · report date 2025-03-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 107,558 F2: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of restricted stock units and does not represent a discretionary sale by the holder.
F2: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 12, 2026 22:00 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 24,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010575 · ownership.xml · derivative · entry 3 Segal Lloyd Mitchell · CIK 0001477123 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 6,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · derivative.exercise_date: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · derivative.expiration_date: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 22:00 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010575 · ownership.xml · derivative · entry 2 Segal Lloyd Mitchell · CIK 0001477123 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 13,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · derivative.exercise_date: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · derivative.expiration_date: The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 22:00 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionCommon Stock | 19,631 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-010575 · ownership.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 19,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration. F1 · price: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration. F2 · ownership.nature: Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:30 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Shares | 21,179 | $1.14 | $24,144.06 |
DisclosureSEC source: 0001415889-25-008105 · form4-03142025_040309.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,394 F1 · kind: Represent shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of restricted stock units and does not represent a discretionary sale by the holder. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:00 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantEmployee Stock Option (right to buy) · Derivative | 237,000 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001415889-25-007239 · form4-03062025_050306.xml · derivative · entry 3 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,000 Underlying: Common Shares · 237,000 shares Expires 2035-03-03 F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on March 4, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:00 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007239 · form4-03062025_050306.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,573 F1 · shares: Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 4, 2026, March 4, 2027 and March 4, 2028, subject to Reporting Person continuing to provide service through each such date. F2 · balance_after: Includes 895 and 2,000 shares acquired on August 15, 2024 and February 15, 2025, respectively, under the Issuer's employee stock purchase plan. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 01:31 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Shares | 2,491 | $4.63 | $11,533.33 |
DisclosureSEC source: 0001415889-24-009629 · form4-04022024_010432.xml · nonDerivative · entry 2 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 107,558 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.65 inclusive. F4 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| March 28, 2024 Filed Apr 2, 2024 01:31 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Shares | 2,650 | $4.62 | $12,243.00 |
DisclosureSEC source: 0001415889-24-009629 · form4-04022024_010432.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 110,049 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). F3 · balance_after: The change in the total shares prior to the transactions reported herein reflects a change in form of ownership from direct to indirect, which was exempt from reporting pursuant to Rule 16a-13. F4 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| March 27, 2024 Filed Mar 27, 2024 22:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Shares | 2,650 | $4.63 | $12,269.50 |
DisclosureSEC source: 0001415889-24-009249 · form4-03272024_100342.xml · nonDerivative · entry 3 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 83,866 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.77 inclusive. F3 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| March 26, 2024 Filed Mar 27, 2024 22:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Shares | 2,650 | $4.64 | $12,296.00 |
DisclosureSEC source: 0001415889-24-009249 · form4-03272024_100342.xml · nonDerivative · entry 2 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 86,516 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.83 inclusive. F3 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 22:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Shares | 2,650 | $4.79 | $12,693.50 |
DisclosureSEC source: 0001415889-24-009249 · form4-03272024_100342.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 89,166 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5). F3 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:04 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantEmployee Stock Option (right to buy) · Derivative | 237,000 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0001415889-24-006464 · form4-03052024_020338.xml · derivative · entry 3 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,000 Underlying: Common Shares · 237,000 shares Expires 2034-02-28 F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on March 1, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:04 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006464 · form4-03052024_020338.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,677 F1 · shares: Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 1, 2025, March 1, 2026 and March 1, 2027, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 02:44 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantEmployee Stock Option (right to buy) · Derivative | 344,200 | $0.00 Strike: $12.42 | $0.00 |
DisclosureSEC source: 0001209191-23-006062 · doc4.xml · derivative · entry 3 Segal Lloyd Mitchell · CIK 0001477123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,200 Underlying: Common Shares · 344,200 shares Expires 2033-01-29 F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on January 30, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 02:44 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantCommon Shares | 78,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006062 · doc4.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,677 F1 · shares: Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of January 30, 2024, January 30, 2025 and January 30, 2026, subject to Reporting Person continuing to provide service through each such date. F2 · balance_after: Includes 398 shares and 729 shares acquired on August 13, 2021 and February 15, 2022, respectively, under the Issuer's employee stock purchase plan. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 21:55 UTC Amendment | Repare Therapeutics Inc. RPTX · Entity 68433 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $15.63 | $0.00 |
DisclosureSEC source: 0001209191-22-004623 · doc4a.xml · derivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2032-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This Form 4 amendment is being filed to correct the original Form 4 filed on January 20, 2022. The original Form 4 was filed early with an incorrect Transaction Date due to a clerical error. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on January 18, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $15.63 | $0.00 |
DisclosureSEC source: 0001209191-22-004045 · doc4.xml · derivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2032-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on January 18, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 1,542 | $35.61 | $54,910.62 |
DisclosureSEC source: 0001209191-21-044032 · doc4.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 94,466 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F2 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 22:35 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 1,576 | $35.00 | $55,160.00 |
DisclosureSEC source: 0001209191-21-039621 · doc4.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 96,008 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F2 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 22:36 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-21-038747 · doc4.xml · derivative · entry 6 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,683 Underlying: Common Stock · 5,000 shares Expires 2027-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 22:36 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 5,000 | $31.25 | $156,250.00 |
DisclosureSEC source: 0001209191-21-038747 · doc4.xml · nonDerivative · entry 5 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.49 inclusive. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 22:36 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | Exercise / conversionCommon Stock | 5,000 | $1.64 | $8,185.00 |
DisclosureSEC source: 0001209191-21-038747 · doc4.xml · nonDerivative · entry 4 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 22:36 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 12,172 | $31.36 | $381,713.92 |
DisclosureSEC source: 0001209191-21-038747 · doc4.xml · nonDerivative · entry 3 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 97,584 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.215 to $31.65 inclusive. F2 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 22:36 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 17,180 | $30.64 | $526,395.20 |
DisclosureSEC source: 0001209191-21-038747 · doc4.xml · nonDerivative · entry 2 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 109,756 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.19 inclusive. F2 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 22:36 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 6,648 | $31.74 | $211,007.52 |
DisclosureSEC source: 0001209191-21-038747 · doc4.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 126,936 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5). F2 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:02 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 3,770 | $35.03 | $132,065.36 |
DisclosureSEC source: 0001209191-21-034874 · doc4.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 133,584 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F2 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:19 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 3,800 | $35.06 | $133,228.00 |
DisclosureSEC source: 0001209191-21-034571 · doc4.xml · nonDerivative · entry 2 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 137,354 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.25, inclusive. F2 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| May 18, 2021 Filed May 20, 2021 22:19 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 1,800 | $35.00 | $63,000.00 |
DisclosureSEC source: 0001209191-21-034571 · doc4.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 141,154 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F2 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 21:44 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Stock | 5,512 | $35.01 | $192,975.12 |
DisclosureSEC source: 0001209191-21-027344 · doc4.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 142,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 02:04 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $36.91 | $0.00 |
DisclosureSEC source: 0001209191-21-009487 · doc4.xml · derivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-02-08 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:00 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | PurchaseCommon Stock | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0001209191-20-038975 · doc4.xml · nonDerivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 12:07 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantEmployee Stock Option (right to buy) · Derivative | 354,668 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037782 · doc4.xml · derivative · entry 1 Segal Lloyd Mitchell · CIK 0001477123 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,668 Underlying: Common Stock · 354,668 shares Expires 2030-06-18 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on June 18, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.